Drug Profile
Radalbuvir - Gilead Sciences
Alternative Names: GS-9669Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases
- Class Amides; Antivirals; Carboxylic acids; Cyclohexanes; Cyclohexenes; Small molecules; Thiophenes
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 24 Sep 2021 Discontinued - Phase-I for Hepatitis C in Puerto Rico (PO), before September 2021 (Gilead pipeline, September 2021)
- 24 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in New Zealand (PO), before September 2021 (Gilead pipeline, September 2021)
- 24 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in USA (PO), before September 2021 (Gilead pipeline, September 2021)